Log In
Print this Print this

epoetin alfa (Binocrit) (HX575)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBiosimilar version of erythropoietin (EPO)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia in patients with chronic renal failure (CRF); Treat cancer chemotherapy-associated anemia; Treat cancer treatment-associated anemia
Regulatory Designation

EU - Biosimilar (Treat cancer chemotherapy-associated anemia);
EU - Biosimilar (Treat anemia in patients with chronic renal failure (CRF))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today